Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2021-01-22 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the expansion of the company's intellectual property portfolio with new patents granted in Russia, India, and China. It discusses the strategic importance of these patents and the company's future plans but does not contain any financial statements, detailed financial performance data, or regulatory filings. It is not an earnings release, annual report, or any form of financial report. It is also not a regulatory filing or certification. The document is a corporate announcement about intellectual property and business development, which fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-01-22 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a second clinical study site in the US for a Phase II bladder cancer clinical study by Theralase Technologies Inc. It provides details about the clinical study, the sites involved, and some background on the company and the study endpoints. There are no financial statements, regulatory filings, or detailed financial data. The document is a corporate announcement about clinical trial progress rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a press release about clinical study progress, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-01-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a clinical study site in the US for a Phase II bladder cancer clinical study by Theralase Technologies Inc. It discusses clinical trial details, Institutional Review Board approvals, study endpoints, and forward-looking statements. There is no financial data, earnings information, regulatory filing, or management discussion of financial results. The content is focused on clinical study progress and company announcements related to research activities. This type of document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like earnings release, annual report, or investor presentation.
2021-01-19 English
News release - English.pdf
Regulatory Filings
2021-01-09 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the launch of a new clinical study site for a Phase II clinical study related to a pharmaceutical company's drug development. It discusses clinical trial details, study endpoints, regulatory guidance from the FDA, and forward-looking statements about the company's plans and risks. There are no financial statements, earnings data, or detailed management analysis. The document is not a regulatory filing, audit report, or management change announcement. It is a corporate announcement about clinical trial progress and regulatory status, typical of a press release or capital/financing update related to clinical development progress. Given the focus on clinical study launch and regulatory status, it fits best under Capital/Financing Update (CAP) as it relates to company development activities and potential future financing implications. The document length (8380 characters) and content do not indicate it is a report publication announcement or regulatory filing. Confidence is high due to clear clinical study and regulatory update focus.
2020-12-07 English
News release - English.pdf
Regulatory Filings
2020-11-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.